Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma.

Abstract

AIM:

The aim of the present study was to retrospectively evaluate the role of S-1-based chemotherapy for patients with relapsed advanced thymic carcinoma (TC).

PATIENTS AND METHODS:

This study was a retrospective review of TC patients who had received S-1-based chemotherapy for patients with platinum- and antrathycline-failure TC. Patients received S-1 monotherapy or S-1/gemcitabine combination therapy, that were repeated until disease progression.

RESULTS:

The patients consisted of 4 males and 4 females with a median age of 59 years (range=41-71); 2 with squamous cell carcinoma, 3 with undifferentiated carcinoma, 1 with poorly-differentiated neuroendocrine carcinoma and 2 not otherwise specified. Grade 3 or higher toxicity was only neutropenia (25.0%). No treatment-related death was observed. The response rate was 50.0% (95% confidence interval (CI)=21.5-78.5%). The median progression free-survival (PFS) and overall survival (OS) of S-1-based chemotherapy were 6.0 and 13.5 months, respectively.

CONCLUSION:

S-1-based chemotherapy was found to be potentially useful for patients with relapsed TC.

• Authors: Fumihiko Hirai, Takashi Seto, Eiko Inamasu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Yukito Ichinose
• Journal: Anticancer research (Anticancer Res) Vol. 34 Issue 10 Pg. 5743-7 (Oct 2014) ISSN: 1791-7530 [Electronic] Greece
• PMID: 25275083 (Publication Type: Journal Article)
• Copyright: Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Platinum
• Oxonic Acid

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Staging
• Oxonic Acid (administration & dosage)
• Platinum (therapeutic use)
• Tegafur (administration & dosage)
• Thymoma (drug therapy, pathology)
• Thymus Neoplasms (drug therapy, mortality, pathology)
• Treatment Outcome